Open for Enrollment Soon
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

SEER-2 (Neurotrophic Keratopathy) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an investigational drug called RGN-259 Thymosin Beta 4 eye drops solution (the study drug) is a safe and effective option for the treatment of neurotrophic keratopathy.

What is the Condition Being Studied?

Neurotrophic Keratopathy

Who Can Participate in the Study?

Adults ages 18+ who:

- Have persistent epithelial defect in one or both eyes

- Are diagnosed with neurotrophic keratopathy

- Have not had any eye surgery for the last 3 months

For more information about who can be in this study, please contact the study team at

Age Group

What is Involved?

If you choose to join the study, you will

- Get a random assignment (like a coin flip) to receive either the study drug or a placebo (sterile saline solution)

- Visit our clinic at the Duke Eye Center up to 7 times

- Keep in touch with the study team for up to 6 weeks

During the study visits, you will have eye exams and vision tests, and you will answer some questionnaires.

Study Details

Full Title
A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2) - RGN-NK-302
Principal Investigator
Corneal Specialist
Protocol Number
IRB: PRO00113615
NCT: NCT05555589
Phase III
Enrollment Status
Open for Enrollment Soon